Ryan Davies
Chief Executive Officer
Biotech, VC, Entrepreneur
Salt Lake City, UT, USA
Listen to Ryan’s Podcast!
Ryan Davies is the CEO of CancerVAX.
Ryan Davies has had a successful career as an entrepreneur, business executive and public servant. Prior to founding CancerVAX, Ryan co-founded several biotech companies/technologies including a nitric oxide topical wound-care product, a medical device company (drug delivery system) and an antibiotic development company.
Ryan Davies served as CEO of Curza, a small molecule therapeutics company focused on developing new antibiotics; SVP at Clarke Capital Partners, a private growth equity investment firm; co-founder of a software/ecommerce company Found.com (acquired by CRS Retail Systems); co-founder of a software company O2 Blue (acquired by Prebon Yamane). His public service activities include serving on the Draper City Council (Utah) and serving on the campaigns of two U.S. presidential campaigns, one U.S. senate campaign and two gubernatorial campaigns. Ryan holds degrees in Business Management from Ricks College and Political Science from Brigham Young University.
CancerVAX is a pre-clinical biotechnology company working with UCLA to develop immunotherapy cancer treatments that use the body’s immune system to fight cancer. Their aim is to develop transformative therapies to protect and improve people’s lives. By leveraging cutting-edge bioengineering and molecular technologies, CancerVAX is on a quest to develop a breakthrough Universal Cancer Vaccine. Similar to the way COVID-19 vaccines train the body to recognize and destroy the coronavirus, they are developing a universal cancer vaccine that uses the body’s immune system to detect, mark and destroy cancer cells.
Ryan Davies is also featured on our premiere Features Page, and you can read their podcast interview transcript.
